The Billion-Dollar Business of Adding Years to Life
At the invitation-only Longevity Investors Lunch alongside Davos, family offices, founders and investors explored translating geroscience into investable products. Conversations highlighted personalized biological profiling, genetic compatibility testing, organs-on-chips and the booming market for GLP-1 agonists, framing longevity as a major investment theme tied to Medicine 3.0.
Why it mattersFamily offices accelerating investments in GLP-1 therapies signal managers must prioritize biotech due diligence.